APO Research
Talk to an analyst

APO RESEARCH · REPORT

Generic Injectable Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Generic Injectable Drugs Market Analysis and Forecast 2026-2032

21 December 2025196 pages

Choose your research edition.

Industry ResearchGeneric Injectable Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Generic Injectable Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Generic Injectable Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Generic Injectable Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Generic Injectable Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Generic Injectable Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Generic Injectable Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Generic Injectable Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Generic Injectable Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Generic Injectable Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Generic Injectable Drugs include Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical and Auromedics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Generic Injectable Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Generic Injectable Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Generic Injectable Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Generic Injectable Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Generic Injectable Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Generic Injectable Drugs revenue, projected growth trends, production technology, application and end-user industry.

Generic Injectable Drugs Segment by Company

Hospira (Pfizer Inc.)

Fresenius Kabi

Sandoz (Novartis)

Hikma Pharmaceuticals PLC

Dr. Reddy’s Laboratories Ltd

Grifols

Nichi-Iko Group (Sagent)

Teva Pharmaceutical

Auromedics

Sanofi

Gland Pharma

Endo International PLC

Generic Injectable Drugs Segment by Type

Small Molecule

Large Molecule

Generic Injectable Drugs Segment by Application

Oncology

Anesthesia

Anti-Infectives

Parenteral Nutrition

Cardiovascular Diseases

Generic Injectable Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Injectable Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Generic Injectable Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Injectable Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Generic Injectable Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Generic Injectable Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic Injectable Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Generic Injectable Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Small Molecule Major Player Table 3. Large Molecule Major Player Table 4. Global Generic Injectable Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Oncology Major Player Table 6. Anesthesia Major Player Table 7. Anti-Infectives Major Player Table 8. Parenteral Nutrition Major Player Table 9. Cardiovascular Diseases Major Player Table 10. Generic Injectable Drugs Industry Trends Table 11. Generic Injectable Drugs Industry Drivers Table 12. Generic Injectable Drugs Industry Opportunities and Challenges Table 13. Generic Injectable Drugs Industry Restraints Table 14. Global Generic Injectable Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Generic Injectable Drugs Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Generic Injectable Drugs Market Share by Region (2021-2026) Table 17. Global Generic Injectable Drugs Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Generic Injectable Drugs Market Share by Region (2027-2032) Table 19. Global Generic Injectable Drugs Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Generic Injectable Drugs Revenue Market Share by Players (2021-2026) Table 21. Global Generic Injectable Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Generic Injectable Drugs Key Players Headquarters & Area Served Table 23. Global Generic Injectable Drugs Players, Product Type & Application Table 24. Global Generic Injectable Drugs Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Generic Injectable Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Generic Injectable Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Generic Injectable Drugs Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Generic Injectable Drugs Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Generic Injectable Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Generic Injectable Drugs Revenue Market Share by Type (2027-2032) Table 32. Global Generic Injectable Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Generic Injectable Drugs Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Generic Injectable Drugs Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Generic Injectable Drugs Revenue Market Share by Application (2021-2026) Table 36. Global Generic Injectable Drugs Revenue Market Share by Application (2027-2032) Table 37. Hospira (Pfizer Inc.) Company Information Table 38. Hospira (Pfizer Inc.) Business Overview Table 39. Hospira (Pfizer Inc.) Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Hospira (Pfizer Inc.) Generic Injectable Drugs Product Portfolio Table 41. Hospira (Pfizer Inc.) Recent Development Table 42. Fresenius Kabi Company Information Table 43. Fresenius Kabi Business Overview Table 44. Fresenius Kabi Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Fresenius Kabi Generic Injectable Drugs Product Portfolio Table 46. Fresenius Kabi Recent Development Table 47. Sandoz (Novartis) Company Information Table 48. Sandoz (Novartis) Business Overview Table 49. Sandoz (Novartis) Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Sandoz (Novartis) Generic Injectable Drugs Product Portfolio Table 51. Sandoz (Novartis) Recent Development Table 52. Hikma Pharmaceuticals PLC Company Information Table 53. Hikma Pharmaceuticals PLC Business Overview Table 54. Hikma Pharmaceuticals PLC Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Hikma Pharmaceuticals PLC Generic Injectable Drugs Product Portfolio Table 56. Hikma Pharmaceuticals PLC Recent Development Table 57. Dr. Reddy’s Laboratories Ltd Company Information Table 58. Dr. Reddy’s Laboratories Ltd Business Overview Table 59. Dr. Reddy’s Laboratories Ltd Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Dr. Reddy’s Laboratories Ltd Generic Injectable Drugs Product Portfolio Table 61. Dr. Reddy’s Laboratories Ltd Recent Development Table 62. Grifols Company Information Table 63. Grifols Business Overview Table 64. Grifols Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Grifols Generic Injectable Drugs Product Portfolio Table 66. Grifols Recent Development Table 67. Nichi-Iko Group (Sagent) Company Information Table 68. Nichi-Iko Group (Sagent) Business Overview Table 69. Nichi-Iko Group (Sagent) Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Nichi-Iko Group (Sagent) Generic Injectable Drugs Product Portfolio Table 71. Nichi-Iko Group (Sagent) Recent Development Table 72. Teva Pharmaceutical Company Information Table 73. Teva Pharmaceutical Business Overview Table 74. Teva Pharmaceutical Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Teva Pharmaceutical Generic Injectable Drugs Product Portfolio Table 76. Teva Pharmaceutical Recent Development Table 77. Auromedics Company Information Table 78. Auromedics Business Overview Table 79. Auromedics Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Auromedics Generic Injectable Drugs Product Portfolio Table 81. Auromedics Recent Development Table 82. Sanofi Company Information Table 83. Sanofi Business Overview Table 84. Sanofi Generic Injectable Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Sanofi Generic Injectable Drugs Product Portfolio Table 86. Sanofi Recent Development Table 87. Gland Pharma Company Information Table 88. Gland Pharma Business Overview Table 89. Gland Pharma Generic Injectable Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Gland Pharma Generic Injectable Drugs Product Portfolio Table 91. Gland Pharma Recent Development Table 92. Endo International PLC Company Information Table 93. Endo International PLC Business Overview Table 94. Endo International PLC Generic Injectable Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Endo International PLC Generic Injectable Drugs Product Portfolio Table 96. Endo International PLC Recent Development Table 97. North America Generic Injectable Drugs Revenue by Type (2021-2026) & (US$ Million) Table 98. North America Generic Injectable Drugs Revenue by Type (2027-2032) & (US$ Million) Table 99. North America Generic Injectable Drugs Revenue by Application (2021-2026) & (US$ Million) Table 100. North America Generic Injectable Drugs Revenue by Application (2027-2032) & (US$ Million) Table 101. North America Generic Injectable Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 102. North America Generic Injectable Drugs Revenue by Country (2021-2026) & (US$ Million) Table 103. North America Generic Injectable Drugs Revenue by Country (US$ Million) & (2027-2032) Table 104. Europe Generic Injectable Drugs Revenue by Type (2021-2026) & (US$ Million) Table 105. Europe Generic Injectable Drugs Revenue by Type (2027-2032) & (US$ Million) Table 106. Europe Generic Injectable Drugs Revenue by Application (2021-2026) & (US$ Million) Table 107. Europe Generic Injectable Drugs Revenue by Application (2027-2032) & (US$ Million) Table 108. Europe Generic Injectable Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. Europe Generic Injectable Drugs Revenue by Country (2021-2026) & (US$ Million) Table 110. Europe Generic Injectable Drugs Revenue by Country (US$ Million) & (2027-2032) Table 111. China Generic Injectable Drugs Revenue by Type (2021-2026) & (US$ Million) Table 112. China Generic Injectable Drugs Revenue by Type (2027-2032) & (US$ Million) Table 113. China Generic Injectable Drugs Revenue by Application (2021-2026) & (US$ Million) Table 114. China Generic Injectable Drugs Revenue by Application (2027-2032) & (US$ Million) Table 115. Asia Generic Injectable Drugs Revenue by Type (2021-2026) & (US$ Million) Table 116. Asia Generic Injectable Drugs Revenue by Type (2027-2032) & (US$ Million) Table 117. Asia Generic Injectable Drugs Revenue by Application (2021-2026) & (US$ Million) Table 118. Asia Generic Injectable Drugs Revenue by Application (2027-2032) & (US$ Million) Table 119. Asia Generic Injectable Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 120. Asia Generic Injectable Drugs Revenue by Region (US$ Million) & (2021-2026) Table 121. Asia Generic Injectable Drugs Revenue by Region (US$ Million) & (2027-2032) Table 122. SAMEA Generic Injectable Drugs Revenue by Type (2021-2026) & (US$ Million) Table 123. SAMEA Generic Injectable Drugs Revenue by Type (2027-2032) & (US$ Million) Table 124. SAMEA Generic Injectable Drugs Revenue by Application (2021-2026) & (US$ Million) Table 125. SAMEA Generic Injectable Drugs Revenue by Application (2027-2032) & (US$ Million) Table 126. SAMEA Generic Injectable Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 127. SAMEA Generic Injectable Drugs Revenue by Country (2021-2026) & (US$ Million) Table 128. SAMEA Generic Injectable Drugs Revenue by Country (US$ Million) & (2027-2032) Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Generic Injectable Drugs Image Figure 2. Global Generic Injectable Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Generic Injectable Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Small Molecule Image Figure 5. Large Molecule Image Figure 6. Global Generic Injectable Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Generic Injectable Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Oncology Image Figure 9. Anesthesia Image Figure 10. Anti-Infectives Image Figure 11. Parenteral Nutrition Image Figure 12. Cardiovascular Diseases Image Figure 13. Global Generic Injectable Drugs Market Size (US$ Million) & (2021-2032) Figure 14. Global Generic Injectable Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Generic Injectable Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Generic Injectable Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Generic Injectable Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Generic Injectable Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Generic Injectable Drugs Revenue Market Share by Type (2021-2032) Figure 21. Global Generic Injectable Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Generic Injectable Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Generic Injectable Drugs Revenue Market Share by Application (2021-2032) Figure 24. North America Generic Injectable Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Generic Injectable Drugs Revenue Share by Type (2021-2032) Figure 26. North America Generic Injectable Drugs Revenue Share by Application (2021-2032) Figure 27. North America Generic Injectable Drugs Revenue Share by Country (2021-2032) Figure 28. United States Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Generic Injectable Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Generic Injectable Drugs Revenue Share by Type (2021-2032) Figure 33. Europe Generic Injectable Drugs Revenue Share by Application (2021-2032) Figure 34. Europe Generic Injectable Drugs Revenue Share by Country (2021-2032) Figure 35. Germany Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Generic Injectable Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Generic Injectable Drugs Revenue Share by Type (2021-2032) Figure 45. China Generic Injectable Drugs Revenue Share by Application (2021-2032) Figure 46. Asia Generic Injectable Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Generic Injectable Drugs Revenue Share by Type (2021-2032) Figure 48. Asia Generic Injectable Drugs Revenue Share by Application (2021-2032) Figure 49. Asia Generic Injectable Drugs Revenue Share by Region (2021-2032) Figure 50. Japan Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Generic Injectable Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Generic Injectable Drugs Revenue Share by Type (2021-2032) Figure 58. SAMEA Generic Injectable Drugs Revenue Share by Application (2021-2032) Figure 59. SAMEA Generic Injectable Drugs Revenue Share by Country (2021-2032) Figure 60. Brazil Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Generic Injectable Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecule
  • Large Molecule
Applications
  • Oncology
  • Anesthesia
  • Anti-Infectives
  • Parenteral Nutrition
  • Cardiovascular Diseases
Companies covered
  • Hospira (Pfizer Inc.)
  • Fresenius Kabi
  • Sandoz (Novartis)
  • Hikma Pharmaceuticals PLC
  • Dr. Reddy’s Laboratories Ltd
  • Grifols
  • Nichi-Iko Group (Sagent)
  • Teva Pharmaceutical
  • Auromedics
  • Sanofi
  • Gland Pharma
  • Endo International PLC

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Generic Injectable Drugs Market by Type
  3. 1.2.1 Global Generic Injectable Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Small Molecule
  5. 1.2.3 Large Molecule
  6. 1.3 Generic Injectable Drugs Market by Application
  7. 1.3.1 Global Generic Injectable Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Oncology
  9. 1.3.3 Anesthesia
  10. 1.3.4 Anti-Infectives
  11. 1.3.5 Parenteral Nutrition
  12. 1.3.6 Cardiovascular Diseases
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Generic Injectable Drugs Market Dynamics
  1. 2.1 Generic Injectable Drugs Industry Trends
  2. 2.2 Generic Injectable Drugs Industry Drivers
  3. 2.3 Generic Injectable Drugs Industry Opportunities and Challenges
  4. 2.4 Generic Injectable Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Generic Injectable Drugs Market Perspective (2021-2032)
  2. 3.2 Global Generic Injectable Drugs Growth Trends by Region
  3. 3.2.1 Global Generic Injectable Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Generic Injectable Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Generic Injectable Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Generic Injectable Drugs Revenue by Players
  2. 4.1.1 Global Generic Injectable Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Generic Injectable Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Generic Injectable Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Generic Injectable Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Generic Injectable Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Generic Injectable Drugs Players, Product Type & Application
  8. 4.5 Global Generic Injectable Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Generic Injectable Drugs Market CR5 and HHI
  11. 4.6.3 2025 Generic Injectable Drugs Tier 1, Tier 2, and Tier 3
5 Generic Injectable Drugs Market Size by Type
  1. 5.1 Global Generic Injectable Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Generic Injectable Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Generic Injectable Drugs Revenue Market Share by Type (2021-2032)
6 Generic Injectable Drugs Market Size by Application
  1. 6.1 Global Generic Injectable Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Generic Injectable Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Generic Injectable Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Hospira (Pfizer Inc.)
  2. 7.1.1 Hospira (Pfizer Inc.) Company Information
  3. 7.1.2 Hospira (Pfizer Inc.) Business Overview
  4. 7.1.3 Hospira (Pfizer Inc.) Generic Injectable Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Hospira (Pfizer Inc.) Generic Injectable Drugs Product Portfolio
  6. 7.1.5 Hospira (Pfizer Inc.) Recent Developments
  7. 7.2 Fresenius Kabi
  8. 7.2.1 Fresenius Kabi Company Information
  9. 7.2.2 Fresenius Kabi Business Overview
  10. 7.2.3 Fresenius Kabi Generic Injectable Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Fresenius Kabi Generic Injectable Drugs Product Portfolio
  12. 7.2.5 Fresenius Kabi Recent Developments
  13. 7.3 Sandoz (Novartis)
  14. 7.3.1 Sandoz (Novartis) Company Information
  15. 7.3.2 Sandoz (Novartis) Business Overview
  16. 7.3.3 Sandoz (Novartis) Generic Injectable Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sandoz (Novartis) Generic Injectable Drugs Product Portfolio
  18. 7.3.5 Sandoz (Novartis) Recent Developments
  19. 7.4 Hikma Pharmaceuticals PLC
  20. 7.4.1 Hikma Pharmaceuticals PLC Company Information
  21. 7.4.2 Hikma Pharmaceuticals PLC Business Overview
  22. 7.4.3 Hikma Pharmaceuticals PLC Generic Injectable Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Hikma Pharmaceuticals PLC Generic Injectable Drugs Product Portfolio
  24. 7.4.5 Hikma Pharmaceuticals PLC Recent Developments
  25. 7.5 Dr. Reddy’s Laboratories Ltd
  26. 7.5.1 Dr. Reddy’s Laboratories Ltd Company Information
  27. 7.5.2 Dr. Reddy’s Laboratories Ltd Business Overview
  28. 7.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectable Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Dr. Reddy’s Laboratories Ltd Generic Injectable Drugs Product Portfolio
  30. 7.5.5 Dr. Reddy’s Laboratories Ltd Recent Developments
  31. 7.6 Grifols
  32. 7.6.1 Grifols Company Information
  33. 7.6.2 Grifols Business Overview
  34. 7.6.3 Grifols Generic Injectable Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Grifols Generic Injectable Drugs Product Portfolio
  36. 7.6.5 Grifols Recent Developments
  37. 7.7 Nichi-Iko Group (Sagent)
  38. 7.7.1 Nichi-Iko Group (Sagent) Company Information
  39. 7.7.2 Nichi-Iko Group (Sagent) Business Overview
  40. 7.7.3 Nichi-Iko Group (Sagent) Generic Injectable Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Nichi-Iko Group (Sagent) Generic Injectable Drugs Product Portfolio
  42. 7.7.5 Nichi-Iko Group (Sagent) Recent Developments
  43. 7.8 Teva Pharmaceutical
  44. 7.8.1 Teva Pharmaceutical Company Information
  45. 7.8.2 Teva Pharmaceutical Business Overview
  46. 7.8.3 Teva Pharmaceutical Generic Injectable Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Teva Pharmaceutical Generic Injectable Drugs Product Portfolio
  48. 7.8.5 Teva Pharmaceutical Recent Developments
  49. 7.9 Auromedics
  50. 7.9.1 Auromedics Company Information
  51. 7.9.2 Auromedics Business Overview
  52. 7.9.3 Auromedics Generic Injectable Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Auromedics Generic Injectable Drugs Product Portfolio
  54. 7.9.5 Auromedics Recent Developments
  55. 7.10 Sanofi
  56. 7.10.1 Sanofi Company Information
  57. 7.10.2 Sanofi Business Overview
  58. 7.10.3 Sanofi Generic Injectable Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Sanofi Generic Injectable Drugs Product Portfolio
  60. 7.10.5 Sanofi Recent Developments
  61. 7.11 Gland Pharma
  62. 7.11.1 Gland Pharma Company Information
  63. 7.11.2 Gland Pharma Business Overview
  64. 7.11.3 Gland Pharma Generic Injectable Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Gland Pharma Generic Injectable Drugs Product Portfolio
  66. 7.11.5 Gland Pharma Recent Developments
  67. 7.12 Endo International PLC
  68. 7.12.1 Endo International PLC Company Information
  69. 7.12.2 Endo International PLC Business Overview
  70. 7.12.3 Endo International PLC Generic Injectable Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Endo International PLC Generic Injectable Drugs Product Portfolio
  72. 7.12.5 Endo International PLC Recent Developments
8 North America
  1. 8.1 North America Generic Injectable Drugs Revenue (2021-2032)
  2. 8.2 North America Generic Injectable Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Generic Injectable Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Generic Injectable Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Generic Injectable Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Generic Injectable Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Generic Injectable Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Generic Injectable Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Generic Injectable Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Generic Injectable Drugs Revenue by Country
  11. 8.6.1 North America Generic Injectable Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Generic Injectable Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Generic Injectable Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Generic Injectable Drugs Revenue (2021-2032)
  2. 9.2 Europe Generic Injectable Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Generic Injectable Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Generic Injectable Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Generic Injectable Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Generic Injectable Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Generic Injectable Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Generic Injectable Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Generic Injectable Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Generic Injectable Drugs Revenue by Country
  11. 9.6.1 Europe Generic Injectable Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Generic Injectable Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Generic Injectable Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Generic Injectable Drugs Revenue (2021-2032)
  2. 10.2 China Generic Injectable Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Generic Injectable Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Generic Injectable Drugs Revenue by Type (2027-2032)
  5. 10.3 China Generic Injectable Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Generic Injectable Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Generic Injectable Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Generic Injectable Drugs Revenue by Application (2027-2032)
  9. 10.5 China Generic Injectable Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Generic Injectable Drugs Revenue (2021-2032)
  2. 11.2 Asia Generic Injectable Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Generic Injectable Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Generic Injectable Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Generic Injectable Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Generic Injectable Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Generic Injectable Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Generic Injectable Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Generic Injectable Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Generic Injectable Drugs Revenue by Country
  11. 11.6.1 Asia Generic Injectable Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Generic Injectable Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Generic Injectable Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Generic Injectable Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Generic Injectable Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Generic Injectable Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Generic Injectable Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Generic Injectable Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Generic Injectable Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Generic Injectable Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Generic Injectable Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Generic Injectable Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Generic Injectable Drugs Revenue by Country
  11. 12.6.1 SAMEA Generic Injectable Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Generic Injectable Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Generic Injectable Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst